AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 DEC 2 - (NewsRx.com & NewsRx.net) -- Researchers at the Veterans Affairs Medical Center at Tulane University recently reviewed work being done "on cytotoxic analogs of luteinizing hormone-releasing hormone (LH-RH), somatostatin and bombesin, designed for targeting chemotherapy to peptide receptors on various cancers."
They said "the project is at advanced stages of development and clinical trials are pending."
According to A.V. Schally and colleagues, "Cytotoxic analogs of LH-RH, AN-152, and AN-207, containing doxorubicin (DOX) or 2-pyrrolino-DOX (AN-201), respectively, target LH-RH receptors and can be used for the treatment of prostatic, breast, ovarian and endometrial cancers, and melanomas.
"AN-201 was also incorporated into the cytotoxic analog of somatostatin, AN-238, which can be targeted to receptors for somatostatin in prostatic, renal, mammary, ovarian, gastric, colorectal, and pancreatic cancers, as well as glioblastomas and lung cancers, suppressing the growth of these tumors and their metastases," the researchers wrote.
They continued, "A cytotoxic analog of bombesin AN-215, containing 2-pyrrolino-DOX, was likewise synthesized and successfully tested in ...
Source: HighBeam Research, Chemotherapy targeted to cancers through tumoral hormone receptors.